

### OVERVIEW



- هماراح تتگانوی الآسطح مگلا کتاتح لوسط متسلاً المتحاد ميت متاج لحسم الإيساب التحون الله التحاد ميت متابع التحاد ميت متابع التحاد ا

  - > they lack both cell wall and cell membrane.

    They don't carry out metabolic processes.
  - > viral reproduction uses much of the host's metabolic host Jackmetabolism Jacke Ge machinery.

  - viruses are not affected by antimicrobial agent. المن اختل الميروسات المن اختل الميروسات المن اختل الميروسات المعادلة المن اختل الميروسات المعادلة المن المنادلة المعادلة (nucleus)

#### Structure of viruses

البردي Nucleic acid core: DNA(or)RNA

- Often contain crucial virus-specific enzymes
- Surrounded by protein: "capsid"
- Sometimes an outer lipid "envelope"
- Complete viral particle: "virion"

Capsid

Nucleic acid

Capsid

Nucleic acid

Capsid

Nucleic acid

Some examples of viruses & the diseases they cause are as follows:

#### الم يكي يتكون مايدة viruses:

- Pox viruses (smallpox جَدَريّ the WHO certified the global eradication of smallpox in 1979)
- Herpes viruses
- Herpes viruses

   المترمان المايكور المرابة المرابة
- HSV-1 cause oral herpes (which can include symptoms known as الله بعدي الخدي الخدي الخلام إلى المعمية ووقت انعرص للاد يتطهر عدي عندي الخلام إلى المحافظة المعاطمة المعاطمة ا
- HSV-2 is a sexually transmitted infection that causes genital herpes.
- Cytomegalovirus (CMV) القاب م
  - Adenoviruses (sore throat, conjunctives)
  - Hepadnaoviruses (hepatitis B virus(HBV))
  - Danillomaviruses (warte )



Flexcil - The Smart Study Toolkit & PDF, Annotate, Note




Flexcil - The Smart Study Toolkit & PDF, Annotate, Note

### Warts



Flexcil - The Smart Study Toolkit & PDF, Annotate, Note



Flexcil - The Smart Study Toolkit & PDF, Annotate, Note

### • RNA viruses:

- Orthomyxoviruses (influenza)
- Paramyxoviruses (measles الحصبة, mumps النكاف
- Rubella virus (German measles الحصبة الألمانية)
- Rhabdovirus (rabies داء الكلّب)
- Picornavirus (colds, meningitis, HAV, poliomyelitis شلك الأطفال )
- Hepacivirus (Hepatitis C virus (HCV))
- Retroviruses (AIDS, T-cell lukemia)
- Arenaviruses (lassa fever)
- Arbovirus (yellow fever)

## Poliomyelitis-



richella-merman-meaclec

This Document has been modified with Flexcil app (Android) https://www.fexcil.com




Flexcil - The Smart Study Toolkit & PDF, Annotate, Note


#### Stages of viral replication

- (1) Attachment of the virus to receptors on the host cell surface;
- (2) Entry of the virus through the host cell membrane;
- (3) uncoating of viral nucleic acid;
  - (4) synthesis of early regulatory proteins, eg, nucleic acid polymerases;
  - (5) synthesis of new viral RNA or DNA;
  - (6) integration into the nuclear genome;
  - (7) synthesis of late, structural proteins;
  - (8) assembly (maturation) of viral particles;
  - (9) release from the cell.

Antiviral agents can potentially target any of these steps.



Flexcil - The Smart Study Toolkit & PDF, Annotate, Note



## Agents To Treat Herpes Simplex Virus (HSV), Varicella-zoster Virus (VZV) & Cytomegalovirus (CMV) Infections

- Acyclovir
   Valacyclovir
   Famciclovir
- Penciclover... topical guanosine analogue
- Cidofovir
- Foscarent
- Ganciclovir
- Anti-CMV infections
- Vidarabine... topical adenosine analogue
- Trifluridine... topical pyrimidine analogue
- Docosanol... topical for orolabial herpes (cold sores)

# Acyclovir (acycloguanosine)

- Acyclic guanosine analoge
- Active against HSV1 HSV2 & VZV.

#### 

Template

Administration: topical ointment, intravenous, oral

#### **Mechanism of action:**

- Acyclovir requires three phosphorylation steps for activation
  - converted first to the monophosphate derivative by the virus specified thymidine kinase
  - and then to the di- and triphosphate
     compounds by host cell



Acycloguanosine monophosphate (acyclo-GMP)

Growing strand

Wiral DNA polymerase

Acycloguanosine triphosphate (acyclo-GTP)

P

G III C

## Acyclovir (acycloguanosine)

- 2. In addition, acyclovir that is incorporated into viral DNA acts as a chain terminator because it lacks the 3-hydroxy group necessary for سأد سادة المالة المالة
- Because acyclovir requires the viral kinase for initial phosphorylation, acyclovir is selectively activated—and the active metabolite accumulates— only in infected cells.

  Agdovir)

## Acyclovir (acycloguanosine)



#### PKs:

- IV, oral (poor 15-20%), topical.
- Well distributed throughout the body including CSF.
- Excreted by the kidney.

#### **Adverse effect:**

- topical administration : local irritation .
- oral: headache, diarrhea, nausea.
- IV: transient renal dysfunction at high doses.


#### Resistance:

 can develop in HSV or VZV through alteration in either the viral thymidine kinase or the DNA polymerase

Flexcil - The Smart Study Toolkit & PDF, Annotate

### Valacyclovir

Valacyclovir is the I-valyl ester of acyclovir.



### Famciclovir (prodrug)

- Prodrug of penciclovir
- After oral administration, famciclovir is rapidly deacetylated and oxidized by first-pass metabolism to penciclovir.
  - As with acyclovir, activation by phosphorylation is catalyzed by the virus-specified thymidine kinase in infected cells, followed by competitive inhibition of the viral DNA polymerase to block DNA synthesis.

#### Agents To Treat Cytomegalovirus (CMV) Infections

Valganciclovir... an I-valyl ester prodrug of ganciclovir

- Ganciclovir... an acyclic guanosine analog (an analog of acyclovir that has greater activity against CMV)
- Cidofovir...a cytosine nucleotide analog...does not require phosphorylation
- Foscarent...an inorganic pyrophosphate analog that inhibits herpesvirus DNA polymerase, RNA polymerase, and HIV reverse transcriptase directly without requiring activation by phosphorylation.

TABLE 49-2 Agents to treat cytomegalovirus (CMV) infection.


Agent	Route of Administration	Use	Recommended Adult Dosage <sup>1</sup>	
Valganciclovir	Oral	CMV retinitis treatment	Induction: 900 mg bid × 21 days	
مارس			Maintenance: 900 mg daily	
المطكوك	Oral	CMV prophylaxis (transplant patients)	900 mg daily	
Ganciclovir	Intravenous	CMV retinitis treatment	Induction: 5 mg/kg q12h × 14–21 days	
			Maintenance: 5 mg/kg/d or 6 mg/kg five times per week	
Foscarnet	Intravenous	CMV retinitis treatment	Induction: 60 mg/kg q8h or 90 mg/kg q12h $\times$ 14–21 days	
			Maintenance: 90–120 mg/kg/d	
Cidofovir	Intravenous	CMV retinitis treatment	Induction: 5 mg/kg/wk × 2 weeks Maintenance: 5 mg/kg every week	

### Antihepatitis agents

Viral Hepatitis

The hepatitis viruses thus far identified (A, B, C, D, and E) each have a pathogenesis specifically involving replication in and destruction of hepatocytes.

Of this group, hepatitis B (a DNA virus) and hepatitis C (an RNA virus) are the most common causes of chronic hepatitis cirrhosis, and hepatocellular carcinoma and are the only hepatic viral infections for which therapy is currently available.



Adefovir HEPSERA
Boceprevir VICTRELIS
Entecavir BARACLUDE
Interferon INTRON, AVONEX
Lamivudine EPIVIR-HBV
Pegylated interferon PEGASYS,
PEG-INTRON
Telaprevir INCIVEK

Telaprevir INCIVEK



- Interferons
- Interferons are a family of naturally occurring, inducible glycoproteins that interfere with the ability of viruses to infect cells. The interferons are synthesized by recombinant DNA technology. (عرب المنافلة على المنافلة
- One of the 15 interferon- $\alpha$  glycoproteins, interferon- $\alpha$ -2b has been approved for treatment of hepatitis B and C.

قآفتوا علىه


- Interferons
- In "pegylated" formulations, bis-monomethoxy polyethylene glycol has been covalently attached to either *interferon-\alpha-2a* or  $-\alpha$ -2b to increase the size of the molecule.
  - The larger molecular size delays absorption from the injection site, lengthens the duration of action of the drug, and also decreases its clearance.
  - Injectable preparations of interferon alfa are available for treatment of both HBV and HCV infections (either subcutaneously or intramuscularly)

TABLE 49-6 Drugs used to treat viral hepatitis.

Agent	Indication	Recommended Adult Dosage	Route of Administration			
Nucleoside/nucleotide analogs						
Adefovir dipivoxil <sup>1</sup>	Chronic hepatitis B	10 mg qd	Oral			
Entecavir <sup>1</sup>	Chronic hepatitis B	500 mg qd	Oral			
Lamivudine <sup>1</sup>	Chronic hepatitis B	100 mg qd (150 mg qd if co-infection with HIV is present)	Oral			
Tenofovir <sup>1</sup>	Chronic hepatitis B	300 mg qd	Oral			
Telbivudine <sup>1</sup>	Chronic hepatitis B	600 mg qd	Oral			
Interferons						
Interferon alfa-2b	Chronic hepatitis B	5 million u <u>nits qd or 10 mil</u> lion units <u>three times wee</u> kly	Subcutaneous or intramuscular			
Interferon alfa-2b <sup>1</sup>	Acute hepatitis C	5 million units qd for 3–4 weeks, then 5 million units three times weekly	Subcutaneous or intramuscular			
Pegylated interferon alfa-2a <sup>1</sup>	Chronic hepatitis B	180 mcg once weekly	Subcutaneous			
Pegylated interferon alfa-2a <sup>1</sup>	Chronic hepatitis C	180 mcg once weekly plus ribavirin (800–1200 mg/d)	Subcutaneous			
Pegylated interferon alfa-2b <sup>1</sup>	Chronic hepatitis C	1.5 mcg/k <u>a once weekly w</u> ith ribavirin (800–1200 mg/d)	Subcutaneous			
Protease inhibitors						
Boceprevir	Chronic hepatitis C	800 mg tid × 24–44 weeks with peg-interferon alfa-2a or peg-interferon alfa-2b	Oral			
Telaprevir	Chronic hepatitis C	750 mg tid × 12 weeks with peg- interferon alfa-2a or peg-interferon alfa-2b	Oral			
Polymerase inhibitor						
Sofosbuvir	Chronic hepatitis C	400 mg qd (see text)	Oral			

<sup>&</sup>lt;sup>1</sup>Dose must be reduced in patients with renal insufficiency.

- Mechanism of action: Interferon alfa appears to function by induction of intracellular signals following binding to specific cell membrane receptors, resulting in inhibition of viral penetration, translation, transcription, protein processing, maturation, and release.
- as well as increased host expression of major histocompatibility complex antigens, enhanced phagocytic activity of macrophages, and augmentation of the proliferation and survival of cytotoxic T cells.




- Adverse effects:
- flu-like syndrome (ie, headache, fevers, chills, myalgias, and malaise) that typically occurs within 6 hours after dosing in more than 30% of patients during the first week of therapy and tends to resolve upon continued administration.

#### Lamivudine

Cytosine analog first developed for HIV

Lower dose used for HBV (100 mg/day)



#### MOA فلايوا

It is phosphorylated to the triphosphate which competes with dCTP for incorporation into growing DNA chains, causing chain termination.

 This compound competitively inhibits HBV DNA polymerase at concentrations that have negligible effects on host DNA polymerase.

- **Boceprevir and telaprevir**
- Boceprevir and telaprevir are oral antiviral agents for the adjunctive له علاج صاعد وليس علاح دنيس لله chronic HCV treatment of chronic HCV.
- They are **protease inhibitors**, thus inhibiting viral replication in host cells. ورَيَعْهِ العَمْوَدُونِ عَلَيْهُ الْمُقَاوِمِيةُ الْمُعَاوِمِيةُ They have a low barrier to resistance and, when used as monotherapy, resistance quickly develops. Therefore, boceprevir or telaprevir should be used in combination with peginterferon alfa and ribavirin in order to improve response rates and reduce the emergence of viral resistance.
  - Metabolized by the CYP3A4/5 pathways and are inhibitors of CYP3A4/5 and P-glycoprotein transporter.
  - Co-administration with numerous drugs is contraindicated, including rifampin, ergot derivatives, cisapride, lovastatin, simvastatin, alfuzosin, sildenafil or tadalafil when used for pulmonary hypertension, pimozide, St. John's wort, triazolam, and midazolam.


### Anti-Influenza drugs

### **Anti-Influenza drugs**

#### A. Amantadine/Rimantadine (Inhibitors of viral uncoating)

• Rimantadine is an α-methyl derivative of amantadine معارة عن مستقبل موجود على سطح المايوس MOA: block the M2 proton ion channel of the virus particle and inhibit uncoating of the viral RNA within infected host الفيوس cells, thus preventing its replication. المعارفة واسمهاي المعارفة المعا

# Amantadine and Rimantadine: Mechanism of Action



- Blocks M2 protein channel (type A only)
- Disrupts hydrogen transport, viral uncoating in host cell and therefore viral RNA transcription

#### Pharmacokinetics:

		absorption	Crossing BBB	metabolism	excretion
V	Amantadine	Well absorbed orally	can	Not extensively metabolized	By kidney
ν	Rimantadine	Well absorbed orally	Can't	Extensively by liver	By kidney

Dose reductions are required for both agents in the elderly and in patients with renal insufficiency, and for rimantadine in patients with marked hepatic insufficiency.

#### **Amantadine/ Rimantadine**

#### **Adverse effects:**

- CNS effect (insomnia, dizziness, ataxia, hallucinations, and seizure).
- ➤ Both agents are teratogenic in rodents, and birth defects have been reported after exposure during pregnancy.
- Gl effect ( anorexia , nausea )

Resistance: Change in amino acid of the M2 matrix protein


due to high rates of resistance in both H1N1 and H3N2
 viruses, these agents are no longer recommended for the
 prevention or treatment of influenza.

# B. Oseltamivir (Tamiflu) / Zanamavir

#### **Neuraminidase inhibitors**

- Influenza A & B المتروس MOA: Neuraminidase inhibitors so these

drugs prevent the release of new virions and their spread from






- Oseltamivir:
- orally administered prodrug.
- The dosage is 75 mg twice daily for 5 days for treatment and 75 mg once daily for prevention.
- Zanamavir is administered via oral inhalation.

#### ❖Side effect:

- Oseltamivir: GI symptoms...Taking oseltamivir with food does not interfere with absorption and may decrease nausea and vomiting.
- Zanamavir: cough, throat discomfort, bronchospasm...not recommended for patients with underlying airway disease.






#### ANTIRETROVIRAL AGENTS

#### **ANTIRETROVIRAL AGENTS**

HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS.

\*HIV attaches to CD4 receptors to enter cells( CD4<sup>+</sup> cells).



## Overview of HIV treatment

محالوا يتحالحوا مهاعفات الفزير/

Prior to approval of *zidovudine* in 1987, treatment of HIV infections focused on decreasing the occurrence of opportunistic infections that caused a high degree of morbidity and mortality in AIDS patients.


Today, the viral life cycle is understood, and a combination of drugs is used to suppress replication of HIV and restore the number of CD4 cells and immunocompetence to the host.


This multidrug regimen is commonly referred to as "highly

active antiretroviral therapy," or HAART.

لمأدرية النعم س سكانر اليروس في موهني الايرر

#### ANTIKETKUVIKAL AGENTS





#### ANTIRETROVIRAL AGENTS

- Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIS)
- 2. Nonnucleoside reverse transcriptase inhibitors (NNRTIS)
- 3. Protease inhibitors (PIs)
- 4. CCR5 receptor antagonists
- 5. Fusion inhibitors
- **6. Integrase inhibitors:** raltegravir.

#### **TABLE 49–2** Major antiretroviral drugs.

Subclass	(Prototype)	Other Significant Agents
Nucleoside reverse transcriptase inhibitors	Zidovudine	Abacavir, didano- sine, emtricitabine, lamivudine, stavu- dine, zalcitabine, zidovudine
Nonnucleoside reverse transcriptase inhibitors	Delavirdine	Efavirenz, etravirine, nevirapine, tenofovir
Protease inhibitors	Indinavir	Amprenavir, ata- zanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir
CCR-5 antagonist	Maraviroc	
Fusion inhibitor	Enfuvirtide	

#### ANTIRETROVIRAL AGENTS

Administration of combination antiretroviral therapy, typically including at least three antiretroviral agents has become the standard of care (based on potency, susceptibility and tolerability).

Two nucleoside/-tide reverse transcriptase inhibitors plus

One protease inhibitor

(+ ritonavir)

or

A nonnucleoside reverse transcriptase inhibitor

or

An integrase inhibitor


## NRTIS

- אולישיטלין אונישיט און אונישיט אונישיט און אונישיט אינישיט אונישיט אונישיט אונישיט אינישיט אונישיט אונישיט אינישיט אינישיט אונישיט אינישיט איניש איניש איניש איניש אינישיט איניש איניש איניש איניש איניש איניש איניש איניש איניע אי generally used in combination with other classes of agents, such as an NNRTI, PI, or integrase inhibitor.
- NRTIs are usually given in pairs, and many are available as coformulations in order to decrease pill burden and improve adherence.

  المعنى المعادية المعادي

  - Drug-drug interactions (eg, didanosine plus tenofovir),
  - Similar resistance patterns (eg, lamivudine plus emtricitabine) or
  - 3. Overlapping toxicities (eg, stavudine plus didanosine).


 NRTIs are analogs of native ribosides, which <u>all lack a 3'-</u> <u>hydroxyl group</u>.



Approved in 1987, the first agent available for

treatment of HIV infection

- MOA:
- Once they enter cells, they are <u>phosphorylated by a variety of cellular</u>
  <u>enzymes</u> to the corresponding triphosphate analog, which is preferentially incorporated into the viral DNA by virus reverse transcriptase.



MOA:

المام. The NRTIs act by(competitive inhibition)of HIV-1 reverse transcriptase and incorporation into the growing viral DNA chain causes premature chain termination due to inhibition of binding with the incoming nucleotide (because the 3'hydroxyl group is not present, a 3'-5' phosphodiester bond between an incoming nucleoside triphosphate and the growing DNA chain cannot be formed) UNY JI

- Resistance: مرة وتيميريكاله
- Mutation in the viral reverse transcriptase.

- Pharmacokinetics:
- The NRTIs are primarily <u>renally excreted</u>, and all require dosage adjustment in renal insufficiency <u>except abacavir</u>, which is metabolized by alcohol dehydrogenase and glucuronyl transferase.

- Drug interactions:
- Due to the renal excretion of the NRTIs, there are not many drug interactions encountered with these agents (compared to NNRTIs)

- Adverse effects:
- due to <u>inhibition of the mitochondrial DNA</u> polymerase in certain tissues.
- The dideoxynucleosides, such as zalcitabine, didanosine, and stavudine, have a greater affinity for the mitochondrial DNA polymerase, leading to such toxicities as peripheral neuropathy, pancreatitis, and lipoatrophy.

  (When more than one NRTI is given, care is taken not to have overlapping toxicities).

All of the NRTIs have been associated with a <u>potentially fatal liver toxicity</u> characterized by lactic acidosis and hepatomegaly with steatosis.



#### Nonnucleoside reverse transcriptase inhibitors:

Delavirdine

Etravirine

Efavirenz

Nevirapine

ive

- MOA:
- The NNRTIs bind directly to HIV-1 reverse transcriptase and inhibit its activity.
- The binding site of NNRTIs is near to but distinct from that of NRTIs. Unlike the NRTI agents, NNRTIs neither compete with nucleoside triphosphates من عاملة والماتياح nor require phosphorylation to be active.

لفس) اله Sıte

Resistance:

- Mutation in reverse transcriptase.
- However, there is <u>no cross-resistance</u> between the <u>NNRTIs</u> and the <u>NRTIs</u>; in fact, some nucleoside-resistant viruses display hypersusceptibility to NNRTIs.

#### Nonnucleoside reverse transcriptase inhibitors:

Delavirdine

Etravirine

Efavirenz

Nevirapine

- **Adverse Effects:**
- gastrointestinal intolerance and skin rash.
- **Drug interactions:**
- A limitation to use of NNRTI agents as a component of antiretroviral therapy is their metabolism by the CYP450 system, leading to innumerable potential drug-drug interactions.
- All NNRTI agents are substrates for CYP3A4 and can act as:
- inducers (nevirapine) < inhibitors (delavirdine) کا المان ا

## **Protease inhibitors**

Amprenavir
 Atazanavir
 Darunavir
 Fosamprenavir
 Indinavir
 Lopinavir
 Ritonavir
 Saquinavir
 Indinavir

معاد الألاع أغلب الأدوية يتاومها

- The resistance to the RT led to target the HIV protease
- HIV requires specific protease to generate essential structural proteins of the mature virion core as well as RT itself.
- This enzyme is essential for the final step of viral proliferation

### **Protease inhibitors**

- Adverse effects:
- As a class, PIs are associated with mild-to-moderate nausea, diarrhea, and dyslipidemia. A syndrome of redistribution and accumulation of body fat that results in central obesity, dorsocervical fat enlargement (buffalo hump), peripheral and facial wasting, breast enlargement, and a cushingoid appearance has been observed.
- Drug interactions:
- Drug interactions are a common problem for all protease inhibitors, because they are not only substrates but also potent inhibitors of CYP isozymes.



Figure 38.29
Accumulation of fat at the base of the

neck in a patient receiving a protease inhibitor.

 The inhibitory potency of the compounds lies between that of ritonavir, the most potent inhibitor, and that of saquinavir, the least potent inhibitor of CYP isoenzymes.




Figure 38.30 Drugs that should not be


## **Fusion inhibitor**

**Enfuvirtide** is a 36-amino-acid peptide that binds to the viral transmembrane glycoprotein gp41, preventing viral fusion.

As a peptide, it must be given subcutaneously.

 Most of the adverse effects are related to the injection, including pain, erythema, induration, and nodules, which

occur in almost all patients.



# **CCR5** receptor antagonists

#### Maraviroc

- Because it is well absorbed orally, it is formulated as an oral tablet.
- Maraviroc blocks the CCR5 co-receptor that works together with gp41 to facilitate HIV entry through the membrane into the cell.
- Maraviroc is generally well tolerated.



# **Integrase Inhibitor**

- - Raltegravir is well tolerated, with nausea, headache, and diarrhea as the most common side effects. More serious side effects reported include elevated CK (creatine kinase) with muscle pain and rhabdomyolysis.

# The End